Summary

Eligibility
for people ages 7 years and up (full criteria)
Location
at Torrance, California and other locations
Dates
study started
completion around

Description

Summary

This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.

Official Title

A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia

Keywords

Achondroplasia, Dwarfism, Bone Diseases, Developmental, Bone Diseases, C-Type Natriuretic Peptide, BMN 111, BMN 111 - Subcutaneous Injection

Eligibility

Locations

  • Harbor - UCLA Medical Center
    Torrance California 90509 United States
  • Children's Hospital & Research Center Oakland
    Oakland California 94609 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
BioMarin Pharmaceutical
ID
NCT02724228
Phase
Phase 2 Achondroplasia Research Study
Study Type
Interventional
Participants
About 30 people participating
Last Updated